

If you're concerned about your risk of respiratory syncytial virus (RSV) infection but don't know where to start, this resource may help support you in starting a conversation with your doctor.

Here are some questions you might want to ask:

- When am I most likely to catch RSV?
- Does contact with children increase the risk of catching RSV?
- What are the common symptoms of RSV?
- What respiratory symptoms should I be concerned about?
- How could RSV infection affect someone like me?
- Do chronic health conditions increase my risk of severe RSV?
- How could RSV infection affect my underlying conditions?
- What is my risk of complications due to RSV?
- How long does it take to recover from RSV?
- Do I need to think about RSV if I am travelling?

RSV quick facts

While RSV commonly affects children,^{1,2} RSV infection can also be serious in older adults.³⁻⁶

Hypothetical patient.
For illustration purposes only.

RSV is a common and contagious respiratory virus.^{1,7} RSV usually causes mild symptoms^{1,6} but can cause severe infection in older adults and may lead to hospitalisation,³⁻⁵ partly because the immune system typically weakens as we age.^{1,8,9}

Adults with certain medical conditions are at an increased risk of developing serious RSV infection.^{5,10,11}

These conditions include:



Asthma



Chronic Obstructive
Pulmonary Disease
(COPD)



Congestive
Heart Failure

References: **1.** Kaler J et al. *Cureus* 2023;15(3):e36342. **2.** Kodama F et al. *Infect Dis Clin North Am* 2017;31:767–90. **3.** Saravanos GL et al. *Med J Aust* 2019;210(10):447–53. **4.** Tseng HF et al. *J Infect Dis* 2020;222(8):1298–1310. **5.** Branche AR et al. *Clin Infect Dis* 2022;74(6):1004–11. **6.** Korsten K et al. *Eur Respir J* 2021;57(4):2002688. **7.** Ching NS et al. *J Paediatr Child Health* 2018;54(12):1321–1328. **8.** Ascough S et al. *Lancet Healthy Longev* 2022;3(6):e405–16. **9.** Watson A et al. *Ther Adv Respir Dis* 2021;15: 1753466621995050. **10.** Prasad N et al. *Clin Infect Dis* 2021;73(1):e158–63. **11.** Kujawski SA et al. *PLoS One* 2022;17(3):e0264890.

Trade marks are owned by or licensed to the GSK group of companies. © 2024 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd. Melbourne, VIC. ABN 47 100 162 481. NP-AU-AVU-PINF-240001. Date of GSK approval: December 2024.